South Side biotech company Alung Technologies Inc. has closed a $12 million financing round, with investors about evenly split between existing shareholders and new high net-worth individuals, mostly from southwest Pennsylvania, a company executive said.

Alung makes a medical device that removes carbon dioxide and delivers oxygen to the bloodstream, replacing intubation where oxygen is delivered to the patient through a tube that is placed into the entrance to the lungs. The company’s Hemolung Respiratory Assist System has received priority processing status from the Food and Drug Administration.

Leading the financing round was Mel Pirchesky, president of Shadyside-based Eagle Ventures, with Redlands, Calif.-based Equinox Securities serving as placement agent.

Alung chairman and CEO Peter DeComo said the funds would be used for continuing operations and further validation of the company’s therapies outside the U.S.

Advertise with us

“What makes this financing so exciting is that we think the product will mostly likely impact the lives of millions of people,” Mr. Pirchesky said.

“It has saved lives, significantly reduced costs and dramatically improved the quality for those who have used it.”

Funding from the most recent round will prepare for clinical trials in early 2017, which will be needed for FDA approval, Mr. DeComo said.

“More clinical data is needed to substantiate the therapy,” he said.

Alung was founded in 1997 and employs 28 people, including six in Europe, but the company is not yet profitable, Mr. DeComo said.

Advertise with us

The company’s device has been used successfully on two patients in the U.S., including at the University of Maryland Medical Center last year. Hemolung’s market is estimated to be about $3 billion.

Kris B. Mamula: kmamula@post-gazette.com, 412-263-1699.